Femasys (NASDAQ:FEMY) Given New $8.00 Price Target at Chardan Capital

Femasys (NASDAQ:FEMY) had its price objective lowered by Chardan Capital from $10.00 to $8.00 in a research note released on Wednesday morning,Benzinga reports. The firm currently has a buy rating on the stock.

Separately, HC Wainwright reissued a “buy” rating and issued a $12.00 price objective on shares of Femasys in a research note on Tuesday, November 12th.

Femasys Stock Down 2.8 %

Shares of FEMY opened at $0.95 on Wednesday. The company’s 50-day moving average price is $1.16 and its 200 day moving average price is $1.14. Femasys has a 12-month low of $0.73 and a 12-month high of $2.40. The company has a current ratio of 3.94, a quick ratio of 5.93 and a debt-to-equity ratio of 0.86. The firm has a market cap of $21.82 million, a P/E ratio of -1.18 and a beta of -2.83.

Femasys (NASDAQ:FEMY) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.04). The company had revenue of $0.55 million during the quarter, compared to analysts’ expectations of $0.40 million. Femasys had a negative net margin of 1,435.77% and a negative return on equity of 141.49%. On average, sell-side analysts forecast that Femasys will post -0.79 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Aljian Capital Management LLC acquired a new stake in Femasys in the 3rd quarter valued at about $27,000. XTX Topco Ltd increased its stake in shares of Femasys by 123.9% during the third quarter. XTX Topco Ltd now owns 32,535 shares of the company’s stock worth $36,000 after buying an additional 18,004 shares during the period. Geode Capital Management LLC raised its holdings in Femasys by 9.2% in the third quarter. Geode Capital Management LLC now owns 206,483 shares of the company’s stock valued at $229,000 after acquiring an additional 17,473 shares in the last quarter. Finally, CM Management LLC lifted its stake in Femasys by 6.3% in the second quarter. CM Management LLC now owns 425,000 shares of the company’s stock worth $484,000 after acquiring an additional 25,000 shares during the last quarter. 65.27% of the stock is currently owned by hedge funds and other institutional investors.

About Femasys

Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.